摘要:
It is an objective of the present invention to provide a non-invasive transdermal immunizing technology by which inflammation and lump do not appear at the skin unlike conventional transdermal immunizing methods with subcutaneous administration and the development amount of antibody in serum is increased. The S/O type transdermal immunizing agent according to the present invention comprises an antigen-surfactant complex and an oil phase; wherein the antigen is covered with the surfactant in the complex; the complex is in a solid state; and the complex is dissolved or dispersed in the oil phase.
摘要:
The present invention provides an external preparation which can improve a skin permeability of a hydrophilic medicine such as NSAID so that the medicine can act directly on a diseased area without passing through gastrointestinal tract or mucosa. The S/O type external preparation external preparation excellent in percutaneous absorbability of the present invention comprises a medicine-containing complex dissolved or dispersed in an oil phase, wherein the complex contains a hydrophilic medicine covered with a surfactant and is in a form of a solid.
摘要:
The present invention provides a pharmaceutical preparation that significantly reduces leakage of a low-molecule medicine in a strong acidic environment, while allowing release of the low-molecule medicine in the enteric canal or the like which is in a weak acidic to neutral environment. The S/O type pharmaceutical preparation of the present invention is characterized in comprising a medicine-containing complex dissolved or dispersed in an oil phase, wherein the complex contains a mixture and a surfactant, the mixture is covered by the surfactant, and the mixture contains a hydrophilic low molecule medicine, and a hydrophilic medicine-leakage-suppressive protein and/or a medicine-leakage-suppressive polysaccharide.
摘要:
It is intended to provide a liquid matrix for medicinal use in which medicine can be easily solubilized, dispersed or suspended and which can be easily swallowed because of being liquid, has favorable working properties in sterilization and so on and a high stability, also exhibits an effect of masking bitterness, and gels in vivo so as to control the release speed of the medicine, and liquid oral preparations using the same. Namely, a liquid matrix which is a liquid assistant for facilitating swallowing medicine characterized in comprising a water-soluble polymer gelling under acidic conditions, and the breaking stress of the gel is about 3.00×103 N/m2 or more. Liquid oral preparations have favorable slow release properties even though being a liquid.
摘要翻译:本发明提供一种医药用液体基质,其中药物易于溶解,分散或悬浮,并且由于液体容易吞咽,在消毒等中具有良好的加工性能和高稳定性,还表现出 掩蔽苦味的效果和体内凝胶,以控制药物的释放速度,以及使用其的液体口服制剂。 即,作为促进吞咽药物的液体助剂的液体基质,其特征在于在酸性条件下含有水溶性聚合物胶凝,凝胶的断裂应力为约3.00×10 3 N / SUP> 2以上。 液体口服制剂即使是液体也具有良好的缓释特性。
摘要:
This invention is intended to improve the solubility and permeability of low-solubility drugs, including drugs hardly soluble in water, classified as Class 2 or 4 in accordance with BCS by modifying such drugs into S/W, S/O, or S/O/W preparations. The S/W, S/O, or S/O/W preparations of low-solubility drugs of this invention are prepared by a method for preparing a composite of a low-solubility drug and surfactant by introducing air or nonflammable gas into the gas phase in the upper portion of a liquid level of the dispersion, dissolution, and emulsification tanks, respectively, at a pressure of 1 to 10 atm.
摘要:
The invention provides a biguanide drug-containing jelly preparation of which discomfort upon administration is decreased by the control of its harshness or bitterness. In addition, the preparation has stability and excellent ability for releasing a drug in the digestive tract. The biguanide drug-containing jelly preparation of the invention is characterized by comprising a biguanide drug, an inorganic acid, and a water-soluble polymer. The jelly preparation of the invention is excellent in both stability and ability for releasing a drug, which are usually incompatible characters, particularly by the action of the inorganic acid.
摘要:
The object of the present invention is to provide a method for treating muscular dystrophy. The method for treating muscular dystrophy according to the present invention is characterized in comprising a step of administering a caldecrin.
摘要:
There is provided an external preparation for wounds which has novel usability in treating skin damages accompanied by a large amount of exudation such as bedsores, skin ulcers, and burns, and yet has such advantages as observed in conventional medicines having been employed in treating these wounds. The external preparation for wounds comprises a water-soluble polymer and a crosslinking agent, and has powdery/granular or ointment form. After absorbing an exudation, the preparation undergoes phase transition from a sol to a gel by the action of ingredient of the preparation, and thus exhibits actions of adsorbing and eliminating necrotic tissues, and protecting the wounded parts. Subsequently, it can continuously absorb the exudation. After being used, it can be easily separated substantially as a mass, thereby exhibiting high therapeutic effects and usability.
摘要:
The object of the present invention is to provide a method for treating muscular dystrophy. The method for treating muscular dystrophy according to the present invention is characterized in comprising a step of administering a caldecrin.
摘要:
The object of the present invention is to provide a drug having therapeutic effect on muscular dystrophy without lowering renal function. The therapeutic drug for muscular dystrophy of the present invention comprises a caldecrin or a caldecrin gene.